Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESMART: Therapeutic Stratification Trial in Pediatric Relapsed/Refractory Tumors
NCT02813135Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Aug 2016
- Primary completion
- Feb 2031
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of ribociclib, adavosertib, olaparib, vistusertib, nivolumab in pediatric cancer, sponsored by Gustave Roussy. Started Aug 2016; status: recruiting.
02
Drugs
03
Conditions
pediatric cancer
Beyond the preview
Go deeper on NCT02813135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813135.